A Post-Marketing Observational Study of VYXEOS to Assess the Incidence of Infusion-Related Reactions in Adult Patients
Status: Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 04 Nov 2019
Price : $35 *
At a glance
- Drugs Cytarabine/daunorubicin (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- Sponsors Jazz Pharmaceuticals Inc
- 29 Oct 2019 Status changed from recruiting to active, no longer recruiting.
- 13 Feb 2019 Planned End Date changed from 1 Jan 2019 to 1 Jan 2020.
- 13 Feb 2019 Planned primary completion date changed from 1 Jan 2019 to 1 Jan 2020.